Delaware (State or Other Jurisdiction of Incorporation) |
000-50767 (Commission File Number) |
04-3523569 (IRS Employer Identification No.) |
60 Westview Street, Lexington, Massachusetts (Address of Principal Executive Offices) |
02421 (Zip Code) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. | ||||||||
SIGNATURE |
Item 5.02. | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. |
| enhance the commercial value of zileuton CR by signing a co-promotion arrangement for zileuton CR, launching zileuton CR following FDA approval, initiating a Phase IIIb clinical trial of zileuton CR, increasing ZYFLO prescriptions and achieving specified business development goals; | |
| progress the research and development pipeline by initiating a Phase II clinical trial of zileuton injection, completing specified preclinical work for the alpha-7 receptor program, establishing a co-development collaboration arrangement for the alpha-7 receptor program and supporting MedImmune in selecting a lead candidate for the HMGB1 program; | |
| establish a strong financial position by managing corporate cash spending and ensuring adequate funding and communicate effectively with investors; and | |
| create an attractive organization by establishing employee programs, recruiting key employees and developing a long-term facility strategy. |
-1-
Date: March 8, 2007 | CRITICAL THERAPEUTICS, INC. |
|||
By: | /s/ Frank E. Thomas | |||
Frank E. Thomas | ||||
President and Chief Executive Officer | ||||